> Interaction studies have only been performed in adults.As EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA d.d. contains EMTRICITABINE and TENOFOVIR DISOPROXIL, any interactions that have been identified with these agents individually may occur with EMTRICITABINE /TENOFOVIR DISOPROXIL Krka d.d. . Interaction studies have only been performed in adults.The steady -state pharmacokinetics of EMTRICITABINE and TENOFOVIR were unaffected when EMTRICITABINE and TENOFOVIR DISOPROXIL were administered together versus each medicinal product dosed alone.In vitro and clinical pharmacokinetic interaction studies have shown the potential for CYP450 mediated interactions involving EMTRICITABINE and TENOFOVIR DISOPROXIL with other medicinal products 9is low.Concomitant us e not recommended
> EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA d.d. should not be administered concomitantly with other medicinal products containing EMTRICITABINE, TENOFOVIR DISOPROXIL, TENOFOVIR ALAFENAMIDE or other cytidine analogues, such as LAMIVUDINE (se e section 4.4). EMTRICITABINE/T enofovir disoproxil Krka d.d.should not be administered concomitantly with ADEFOVIR DIPIVOXIL.DIDANOSINE: The co -administration of EMTRICITABINE/T enofovir disoproxil Krka d.d. and DIDANOSINE is not recommended (see section 4.4 and Table 2).Renally eliminated medicinal products: Since EMTRICITABINE and TENOFOVIR are primarily eliminated by the kidneys, co -administration of EMTRICITABINE/T enofovir disoproxil Krka d.d. with medicinal products that reduce renal function or co mpete for active tubular secretion (e.g. CIDOFOVIR) may increase serum concentrations of EMTRICITABINE, TENOFOVIR and/or the co -administered medicinal products.Use of EMTRICITABINE/T enofovir disoproxil Krka d.d. should be avoided with concurrent or recent use of a nephrotoxic medicinal product. Some examples include, but are not limited to, aminoglycosides, AMPHOTERICIN B, FOSCARNET, GANCICLOVIR, PENTAMIDINE, VANCOMYCIN, CIDOFOVIR or interleukin -2 (see section 4. 4).Other interactions
> Interactions between EMTRICITABINE/TENOFOVIR DISOPROXIL or its individual component(s) and other medicinal products are listed in Table 2 below (increase is indicated as “ ↑”, decrease as “↓”, no change as “↔”, twice daily as “b.i.d.” and once daily as “q.d.”). If available, 90% confidence intervals are shown in parentheses.Table 2: Interactions between the individual components of EMTRICITABINE/TENOFOVIR DISOPROXIL and other medicinal products
> ATAZANAVIR/RITONAVIR/TENOFOVIR DISOPROXIL(300 mg q.d./100 mg q.d./245 mg q.d.) ATAZANAVIR:AUC: ↓ 25% (↓ 42 to ↓ 3)Cmax: ↓ 28% (↓ 50 to ↑ 5)Cmin: ↓ 26% (↓ 46 to ↑ 10)TENOFOVIR:AUC: ↑ 37%Cmax: ↑ 34%Cmin: ↑ 29% No dose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate TENOFOVIR associated adverse events, including renal disorders. Renal function should be closely  monito red (see section 4.4). ATAZANAVIR/RITONAVIR/EMTRICITABINE Interactio n not studied. DARUNAVIR/RITONAVIR/TENOFOVIR DISOPROXIL(300 mg q.d./100 mg q.d./245 mg q.d.) DARUNAVIR:AUC: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 22%Cmin: ↑ 37% No dose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate TENOFOVIR associated adverse events, including renal disorders. Renal function should be closely  monito red (see section 4.4). 10Darunavir/RITONAVIR/EMTRICITABINE Inter actio n not studied. LOPINAVIR/RITONAVIR/TENOFOVIR DISOPROXIL(400 mg b.i.d./100 mg b.i.d/245 mg q.d.) LOPINAVIR/RITONAVIR:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 32% (↑ 25 to ↑ 38)Cmax: ↔Cmin: ↑ 51% (↑ 37 to ↑ 66) No dose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate TENOFOVIR associated adverse events, including renal disorders. Renal function should be closely  monito red (see section 4.4). LOPINAVIR/RITONAVIR/EMTRICITABINE Interactio n not studied. NRTIs
> DIDANOSINE/TENOFOVIR DISOPROXIL Co-administration of TENOFOVIR DISOPROXIL and DIDANOSINE results in a 40 -60% increase in systemic exposure to DIDANOSINE .Co-administration of EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA d.d. and DIDANOSINE is not recommended (see section 4.4). Increased systemic exposure to DIDANOSINE may increase DIDANOSINE related adverse reactions. Rarely, pancreatitis and lactic acidosis, sometimes fatal, have been reported.Co-administration of tenofov ir disoproxil and DIDANOSINE at a dose of 
400 mg daily has been associated with a significant decrease in CD4 cell count, possibly due to an intracellular interaction increasing phosphorylated (i.e. active) DIDANOSINE. A decreased dosage of 250 mg didanosi ne co -administered with TENOFOVIR DISOPROXIL therapy  has been associated with reports of high rates of virological failure within several tested combinatio ns for the treatment of HIV -
1 infection.DIDANOSINE/EMTRICITABINE Interactio n not studied. LAMIVUDINE/TENOFOVIR DISOPROXIL LAMIVUDINE:AUC: ↓ 3% (↓ 8% to ↑ 15)Cmax: ↓ 24% (↓ 44 to ↓ 12)Cmin: NCTenofovir:AUC: ↓ 4% (↓ 15 to ↑ 8)Cmax: ↑ 102% (↓ 96 to ↑ 108)Cmin: NC LAMIVUDINE and EMTRICITABINE/TENOFOVIR DISOPROXIL KRKA d.d. should not be administered concomitantly (see section 4.4). EFAVIRENZ/TENOFOVIR DISOPROXIL EFAVIRENZ:AUC: ↓ 4% (↓ 7 to ↓ 1)Cmax: ↓ 4% (↓ 9 to ↑ 2)Cmin: NCTenofovir:AUC: ↓ 1% (↓ 8 to ↑ 6)Cmax: ↑ 7% (↓ 6 to ↑ 22)Cmin: NC No dose adjustment of EFAVIRENZ is required. ANTI -INFECTIVESHepatitis B virus (HBV) antiviral agents
> LEDIPASVIR/SOFOSBUVIR(90 mg/400 mg q.d.) +ATAZANAVIR/RITONAVIR(300 mg q.d./100 mg q.d.) +EMTRICITABINE/TENOFOVIR DISOPROXIL(200 mg/245 mg q.d.)1Ledipasvir:AUC: ↑ 96% (↑ 74 to ↑ 121)Cmax: ↑ 68% (↑ 54 to ↑ 84)Cmin: ↑ 118% (↑ 91 to ↑ 150)SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072:AUC: ↔Cmax: ↔Cmin: ↑ 42% (↑ 34 to ↑ 49)ATAZANAVIR:AUC: ↔Cmax: ↔Cmin: ↑ 63% (↑ 45 to ↑ 84)RITONAVIR:AUC: ↔Cmax: ↔Cmin: ↑ 45% (↑ 27 to ↑ 64)EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↔Cmax: ↑ 47% (↑ 37 to ↑ 58)Cmin: ↑ 47% (↑ 38 to ↑ 57) Increased plasma concentrations of TENOFOVIR resulting from co -administration of TENOFOVIR DISOPROXIL ,LEDIPASVIR/SOFOSBUVIR and ATAZANAVIR/RITONAVIR may increase adverse reactions related to TENOFOVIR DISOPROXIL ,including renal disorders. The safety of TENOFOVIR d isoproxil when used with LEDIPASVIR/SOFOSBUVIR and a pharmacokinetic enhancer (e.g. RITONAVIR or COBICISTAT) has not been established.The combination should be used with caution with frequent renal monitoring, if other alternatives are not available (see section 4.4). LEDIPASVIR/SOFOSBUVIR(90 mg/400 mg q.d.) +DARUNAVIR/RITONAVIR(800 mg q.d./100 mg q.d.) +EMTRICITABINE/TENOFOVIR DISOPROXIL(200 mg/245 mg q.d.)1Ledipasvir:AUC: ↔Cmax: ↔Cmin: ↔SOFOSBUVIR:AUC: ↓ 27% (↓ 35 to ↓ 18)Cmax: ↓ 37% (↓ 48 to ↓ 25)GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔DARUNAVIR:AUC: ↔Cmax: ↔Cmin: ↔RITONAVIR:AUC: ↔Cmax: ↔Cmin: ↑ 48% (↑ 34 to ↑ 63)EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 50% (↑ 42 to ↑ 59)Cmax: ↑ 64% (↑ 54 to ↑ 74)Cmin: ↑ 59% (↑ 49 to ↑ 70) Increased plasma concentrations of TENOFOVIR resulting from co -administration of TENOFOVIR DISOPROXIL ,LEDIPASVIR/SOFOSBUVIR and DARUNAVIR/RITONAVIR may increase adverse reactions related to TENOFOVIR DISOPROXIL ,including renal dis orders. The safety of TENOFOVIR DISOPROXIL when used with LEDIPASVIR/SOFOSBUVIR and a pharmacokinetic enhancer (e.g. RITONAVIR or COBICISTAT) has not been established.The combination should be used with caution with frequent renal monitoring, if other alt ernatives are not available (see section 4.4). LEDIPASVIR/SOFOSBUVIR(90 mg/400 mg q.d.) +EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL
> LEDIPASVIR:AUC: ↓ 34% (↓ 41 to ↓ 25)Cmax: ↓ 34% (↓ 41 to ↑ 25)Cmin: ↓ 34% (↓ 43 to ↑ 24)No dose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate adverse reactions associated with TENOFOVIR DISOPROXIL ,12(600 mg/200 mg/245 mg q.d.) SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔EFAVIRENZ:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 98% (↑ 77 to ↑ 123)Cmax: ↑ 79% (↑ 56 to ↑ 104)Cmin: ↑ 163% (↑ 137 to ↑ 197) including renal disorders. Renal function should be closely monitored (see section 4.4). LEDIPASVIR/SOFOSBUVIR(90 mg/400 mg q.d.) +EMTRICITABINE/RILPIVIRINE/ TENOFOVIR DISOPROXIL(200 mg/25 mg/245 mg q.d.) LEDIPASVIR:AUC: ↔Cmax: ↔Cmin: ↔SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔RILPIVIRINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 40% (↑ 31 to ↑ 50)Cmax: ↔Cmin: ↑ 91% (↑ 74 to ↑ 110) No dose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate adverse reactions associated with TENOFOVIR DISOPROXIL ,including renal disorders. Renal funct ion should be closely monitored (see section 4.4). LEDIPASVIR/SOFOSBUVIR(90 mg/400 mg q.d.) + DOLUTEGRAVIR (50 mg q.d.) + EMTRICITABINE/TENOFOVIR DISOPROXIL (200 mg/ 245mg q.d.)SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072AUC: ↔Cmax: ↔Cmin: ↔LEDIPASVIR:AUC: ↔Cmax: ↔Cmin: ↔DOLUTEGRAVIR
> AUC: ↔Cmax: ↔Cmin: ↔No dose adjustment is required. The increased exposure of TENOFOVIR could potentiate adverse reactions associated with TENOFOVIR disoprox il, including renal disorders. Renal function should be closely monitored (see section 4.4).13Emtricitabine:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 65% (↑ 59 to ↑ 71)Cmax: ↑ 61% (↑ 51 to ↑ 72)Cmin: ↑ 115% (↑ 105 to ↑ 126)SOFOSBUVIR/VELPATASVIR(400 mg/100 mg q.d.) +ATAZANAVIR/RITONAVIR(300 mg q.d./100 mg q.d.) +EMTRICITABINE/TENOFOVIR DISOPROXIL(200 mg/ 245mg q.d.)SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072:AUC: ↔Cmax: ↔Cmin: ↑ 42% (↑ 37 to ↑ 49)VELPATASVIR:AUC: ↑ 142% (↑ 123 to ↑ 164)Cmax: ↑ 55% (↑ 41 to ↑ 71)Cmin: ↑ 301% (↑ 257 to ↑ 350)ATAZANAVIR:AUC: ↔Cmax: ↔Cmin: ↑ 39% (↑ 20 to ↑ 61)RITONAVIR:AUC: ↔Cmax: ↔Cmin: ↑ 29% (↑ 15 to ↑ 44)EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↔Cmax: ↑ 55% (↑ 43 to ↑ 68)Cmin: ↑ 39% (↑ 31 to ↑ 48)Increased plasma concentrations of TENOFOVIR resulting from co administration of TENOFOVIR DISOPROXIL, SOFOSBUVIR/VELPATASVIR and ATAZANAVIR/RITONAVIR may increase adverse reactions related to TENOFOVIR disoprox il, including renal disorders. The safety of TENOFOVIR DISOPROXIL when used with SOFOSBUVIR/VELPATASVIR and a pharmacokinetic enhancer (e.g. RITONAVIR or COBICISTAT) has not been established.The combination should be used with caution with frequent renal monitoring (see section 4.4).SOFOSBUVIR/VELPATASVIR(400 mg/100 mg q.d.) +DARUNAVIR/RITONAVIR(800 mg q.d./100 mg q.d.) +EMTRICITABINE/TENOFOVIR DISOPROXIL(200 mg/ 245 mg q.d.)SOFOSBUVIR:AUC: ↓ 28% (↓ 34 to ↓ 20)Cmax: ↓ 38% (↓ 46 to ↓ 29)GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔VELPATASVIR:AUC: ↔Cmax: ↓ 24% (↓ 35 to ↓ 11)Cmin: ↔DARUNAVIR:AUC: ↔Cmax: ↔Cmin: ↔Increased plasma concentrations of TENOFOVIR re sulting from co administ ration of TENOFOVIR DISOPROXIL , SOFOSBUVIR/VELPATASVIR and DARUNAVIR/RITONAVIR may increase adverse reactions related to TENOFOVIR disopro xil, including renal disorders.The safety of TENOFOVIR DISOPROXIL when used with SOFOSBUVIR/v elpatasvir and a pharmacokinetic enhancer (e.g. RITONAVIR or COBICISTAT) has not been established.The combination should be used with caution with frequent renal monitoring (see section 4.4).14Ritonavir:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 39% (↑ 33 to ↑ 44)Cmax: ↑ 55% (↑ 45 to ↑ 66)Cmin: ↑ 52% (↑ 45 to ↑ 59)SOFOSBUVIR/VELPATASVIR(400 mg/100 mg q.d.) +LOPINAVIR/RITONAVIR(800 mg/200 mg q.d.) +EMTRICITABINE/TENOFOVIR DISOPROXIL(200 mg/ 245mg q.d.)SOFOSBUVIR:AUC: ↓ 29% (↓ 36 to ↓ 22)Cmax: ↓ 41% (↓ 51 to ↓ 29)GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔VELPATASVIR:AUC: ↔Cmax: ↓ 30% (↓ 41 to ↓ 17)Cmin: ↑ 63% ( ↑ 43 to ↑ 85)LOPINAVIR:AUC: ↔Cmax: ↔Cmin: ↔RITONAVIR:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↔Cmax: ↑ 42% (↑ 27 to ↑ 57)Cmin: ↔Increased plasma concentrations of TENOFOVIR resulting from co administrat ion of TENOFOVIR DISOPROXIL, SOFOSBUVIR/VELPATASVIR and LOPINAVIR/RITONAVIR may increase adverse reactions related to TENOFOVIR disoprox il, including renal disorders. The safety of TENOFOVIR DISOPROXIL when used with SOFOSBUVIR/VELPATASVIR and a pharmacoki netic enhancer (e.g. RITONAVIR or COBICISTAT) has not been established.The combination should be used with caution with frequent renal monitoring (see section 4.4).SOFOSBUVIR/VELPATASVIR(400 mg/100 mg q.d.) +RALTEGRAVIR(400 mg b.i.d) +EMTRICITABINE/TENOFOVIR DISOPROXIL(200 mg/ 245mg q.d.)SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔VELPATASVIR:AUC: ↔Cmax: ↔Cmin: ↔No d ose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate adverse reactions associated with TENOFOVIR disoprox il, including renal disor ders. Renal function should be closely monitored (see section 4.4).15Raltegravir:AUC: ↔Cmax: ↔Cmin: ↓ 21% (↓ 58 to ↑ 48)EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 40% (↑ 34 to ↑ 45)Cmax: ↑ 46% (↑ 39 to ↑ 54)Cmin: ↑ 70% (↑ 61 to ↑ 79)SOFOSBUVIR/VELPATASVIR(400 mg/100 mg q.d.) +EFAVIRENZ/EMTRICITABINE/TENOFOVIR DISOPROXIL(600 mg/200 mg/ 245mg q.d.)SOFOSBUVIR:AUC: ↔Cmax: ↑ 38% (↑ 14 to ↑ 67)GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔VELPATASVIR:AUC: ↓ 53% (↓ 61 to ↓ 43)Cmax: ↓ 47% (↓ 57 to ↓ 36)Cmin: ↓ 57% (↓ 64 to ↓ 48)EFAVIRENZ:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 81% (↑ 68 to ↑ 94)Cmax: ↑ 77% (↑ 53 to ↑ 104)Cmin: ↑ 121% (↑ 100 to ↑ 143)Concomitant administration of SOFOSBUVIR/VELPATASVIR and EFAVIRENZ is expected to decrease plasma concentrations of VELPATASVIR. Co administration of SOFOSBUVIR/VELPATASVIR with EFAVIRENZ -containing regimens is not recommended.SOFOSBUVIR/VELPATASVIR(400 mg/100 mg q.d.) +EMTRICITABINE/RILPIVIRINE/TENOFOVIR DISOPROXIL(200 mg/25 mg/ 245mg q.d.)SOFOSBUVIR:AUC: ↔Cmax: ↔GS-3310072:AUC: ↔Cmax: ↔Cmin: ↔VELPATASVIR:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔No d ose adjustment is recommended. The increased exposure of TENOFOVIR could potentiate adverse reactions associated with te nofovir disoprox il, including renal disorders. Renal function should be closely monitored (see section 4.4).16Rilpivirine:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑ 40% (↑ 34 to ↑ 46)Cmax: ↑ 44% (↑ 33 to ↑ 55)Cmin: ↑ 84% (↑ 76 to ↑ 92)SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR (400 mg/100 mg/
100 mg+100 mg q.d.)3+ DARUNAVIR (800 mg q.d.) + RITONAVIR (100 mg q.d.) + EMTRICITABINE/TENOFOVIR DISOPROXIL (200 mg/245 mg q.d.)SOFOSBUVIR:AUC: ↔Cmax: ↓30%Cmin: N/AGS-3310072:AUC: ↔Cmax:↔Cmin: N/AVelpatasvir:AUC: ↔Cmax: ↔Cmin: ↔VOXILAPREVIR:AUC: ↑143%Cmax:↑72%Cmin: ↑300%DARUNAVIR:AUC: ↔Cmax: ↔Cmin: ↓34%RITONAVIR:AUC: ↑45%Cmax: ↑60%Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔Cmin: ↔TENOFOVIR:AUC: ↑39%Cmax: ↑48%Cmin: ↑47%Increased plasma concentrations of TENOFOVIR resulting from co administration of TENOFOVIR DISOPROXIL, SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR and DARUNAVIR/RITONAVIR may increase adverse reactions related to TENOFOVIR DISOPROXIL, including renal disorders. The safety of TENOFOVIR DISOPROXIL when used with SOFOSBUVIR/velp atasvir/VOXILAPREVIR and a pharmacokinetic enhancer (e.g. RITONAVIR or COBICISTAT) has not been established.The combination should be used with caution with frequent renal monitoring (see section 4.4).SOFOSBUVIR(400 mg q.d.) +EFAVIRENZ/EMTRICITABINE/ TENOFOVIR DISOPROXIL(600 mg/200 mg/245 mg q.d.) SOFOSBUVIR:AUC: ↔Cmax: ↓ 19% (↓ 40 to ↑ 10)GS-3310072:AUC: ↔Cmax: ↓ 23% (↓ 30 to ↑ 16)EFAVIRENZ:AUC: ↔Cmax: ↔Cmin: ↔EMTRICITABINE:AUC: ↔Cmax: ↔No dose adjustment is required. 17Cmin: ↔TENOFOVIR:AUC: ↔Cmax: ↑ 25% (↑ 8 to ↑ 45)Cmin: ↔RIBAVIRIN/TENOFOVIR DISOPROXIL RIBAVIRIN:AUC: ↑ 26% (↑ 20 to ↑ 32)Cmax: ↓ 5% (↓ 11 to ↑ 1)Cmin: NC No dose adjustment of RIBAVIRIN is required. Herpes virus antiviral agents
